[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Heart Care Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":188},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,80,111,148,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100626803","phase-3-triple-oral-therapy-with-bempedoic-acid-vs-usual-care-in-early-lipid-management-of-patients-with-acute-coronary-syndrome-100626803",false,"NCT07440381","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PERSUADE) Trial","PERSUADE","Inclusion Criteria:\n\n* Age ≥18 years\n* Male and females at birth\n* Admitted for ACS caused by an atherothrombotic coronary event;\n* Calculated LDL-c: 70-140 mg\u002FdL within 24 hours from admission for the ACS index event\n* Lipid lowering therapy on admission consisting of a low\u002Fmoderate intensity statin or a high intensity statin (HIS); or no lipid lowering therapy (naïve patients)\n* Lipid-lowering therapy at discharge (at the time of randomization) consisting of HIS or HIS + ezetimibe\n* Scheduled home discharge\n* Written informed consent provided; patients who are unable to give informed consent for any reason will be excluded from the study.\n\nExclusion Criteria:\n\n* Patients already treated with HIS+Ezetimibe on admission for the ACS event,\n* Patients currently, previously or planned to be treated with PCSK9i or inclisiran,\n* Patients treated currently or in the last 3 months with bempedoic acid or in whom this treatment is planned in the following 8 weeks,\n* Known allergy, sensitivity or intolerance to bempedoic acid and\u002For study drugs' formulation ingredients (e.g. lactose intolerance),\n* Patients with history of documented intolerance to statins, ezetimibe or bempedoic acid\n* Patients with known Familial Hypercholesterolemia (FH; heterozygous or homozygous),\n* Patients with plasma triglycerides concentration exceeding 400 mg\u002FdL (4.52 mmol\u002FL),\n* Patients with dysbetalipoproteinemia (type III hyperlipoproteinemia),\n* Unstable clinical status (hemodynamic or electrical instability),\n* Severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 using the CKD-EPI formula),\n* Active liver disease or hepatic dysfunction (AST or ALT levels \\> 3xUNL),\n* Current enrolment in another investigational device or drug study,\n* Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception,\n* Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Early and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrated significant LDL-c reduction and cardiovascular benefit, particularly in statin-intolerant or high-risk patients. However, evidence on early initiation of bempedoic acid during the index ACS hospitalization is currently lacking. The investigators therefore would like to see whether early (pre-discharge) initiation of an oral triple lipid-lowering therapy including bempedoic acid, high-intensity statin (HIS), and ezetimibe is superior to usual care in reducing LDL-c levels at 8 weeks after randomization in patients hospitalized for ACS.",[27,28,29],"Acute Coronary Syndromes","Secondary Prevention","Lipids",[31,32,33,34,35],"ACS","Lipid-lowering therapy","atherothrombotic coronary event","secondary prevention","triple oral lipid lowering therapy","NOT_YET_RECRUITING","2026-02-26",{"date":39,"type":40},"2026-02-27","ACTUAL",{"date":42,"type":21},"2026-09",{"date":44,"type":21},"2027-08",{"name":46,"class":47},"Heart Care Foundation","OTHER",35,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100614762","european-unified-registries-for-heart-care-evaluation-and-randomised-trials-italy-100614762","NCT07283809","European Unified Registries for Heart Care Evaluation and Randomised Trials Italy","European Unified Registries for Heart Care Evaluation and Randomised Trials","EuroHeart ITA","Inclusion Criteria:\n\n* Patients ≥18 years of age.\n* Males and females at birth.\n* At least one of the following clinical conditions:\n* Hospitalization for Acute Coronary Syndrome (ACS)\n* Heart failure (HF, outpatients, and\u002For inpatients)\n* Atrial fibrillation (A Fib, outpatients and\u002For inpatients)\n* Signed informed consent for the study and for privacy.\n\nExclusion Criteria:\n\n* patients who do not sign the consent to participate in the project and\u002For Privacy",{"count":58,"type":21},5000,"12 Months","OBSERVATIONAL","Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and\u002For harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.",[63],"ACS - Acute Coronary Syndrome",[65,31,66,67,68,69],"Quality indicators","STEMI","NSTEMI","ESC","Guidelines","RECRUITING","2026-01-07",{"date":73,"type":40},"2026-01-12",{"date":75,"type":40},"2024-09-15",{"date":77,"type":21},"2027-12-30",{"name":46,"class":47},57,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100612346","early-educational-intervention-to-improve-patient-awareness-on-early-ldl-c-lowering-in-secondary-prevention-100612346","NCT07252388","EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention","Educational Intervention for Patient's Awareness on eaRly LDL-C Lowering Using Novel Pharmacological Strategies in secondarY Prevention (EARLY)","EARLY","Inclusion Criteria:\n\n1. Age ≥18 and \\\u003C80 years old.\n2. Males and females at birth.\n3. Baseline LDL-Cholesterol:\n\n   * ≥ 130 mg\u002Fdl (in statin-naïve patients or who have not followed a stable (unchanged) statin regimen for at least 4 weeks prior to enrollment) or\n   * ≥110 mg\u002Fdl (in patients who have received stable moderate-intensity or low-intensity statin treatment in the 4 weeks prior to enrollment) or\n   * ≥100 mg\u002Fdl (in patients who have received stable treatment with high-intensity statins in the 4 weeks prior to enrollment)\n4. Discharged at home\n5. Ability to understand the requirements of the study and to provide informed consent\n\nExclusion Criteria:\n\n1. Patients who have previously received or currently treated with PCSK9i (evolocumab or alirocumab) or siRNA (inclisiran)\n2. Unstable clinical status (hemodynamic or electrical instability)\n3. Uncontrolled cardiac arrhythmias, defined as recurrent, symptomatic ventricular tachycardia or atrial fibrillation or flutter with rapid ventricular response\n4. Severe renal dysfunction, defined by eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n5. Active liver disease or liver dysfunction, reported in the medical record or defined by AST or ALT levels \\> 3 times the upper limit of normal.\n6. Reported intolerance to statins defined by the following criteria: inability to tolerate at least two different statins; intolerance associated with confirmed and intolerable statin-related adverse effects or significant biomarker abnormalities; improvement\u002Fresolution of symptoms or biomarkers following dose decrease or discontinuation; symptoms or changes in biomarkers not attributable to established predispositions.\n7. Treatment with systemic steroids or systemic cyclosporine within the past 3 months (e.g., intravenously, intramuscularly, or orally)\n8. Known active infection or severe hematologic, metabolic, or endocrine dysfunction as judged by the Investigator.\n9. Current inclusion in other pharmacological and non-pharmacological experimental studies.\n10. Pregnancy. For women of childbearing potential (age \\\u003C 50 years and last menses \\\u003C12 months prior to screening) who have not undergone tubal ligation, oophorectomy, or hysterectomy, pregnancy will be excluded from a pregnancy test prior to inclusion in the study.\n11. Active neoplasia or very severe disease compromising short-medium term life expectancy.\n\nOnly for sites randomized to the interventional group:\n\n• Patients without a device suitable for App use (eg. Smartphone or tablet) or patients that do not consent to receive push notifications by the App.","79 Years",{"count":90,"type":21},240,[92],"NA","Cluster Randomized Trial to test the effectiveness of a patient level delivered educational intervention to improve the awareness on the relevance of obtaining LDL cholesterol recommended goals in patients admitted for an acute coronary syndrome, as compared to usual care. Overall, 24 sites (Coronary Care Units) will be included in the study, 12 randomized to the intervention and 12 to usual care. Overall, 240 patients will be enrolled during an acute coronary syndrome hospitalization.",[27,95],"Chronic Coronary Syndromes",[97,98,99,100,101],"educational intervention","Patient awareness","LDL cholesterol","Lipid lowering drugs","Acute Coronary Syndrome","2025-11-19",{"date":104,"type":40},"2025-11-26",{"date":106,"type":21},"2025-12-11",{"date":108,"type":21},"2027-08-11",{"name":46,"class":47},30,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":135,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100575649","integrated-approach-in-frail-older-people-with-atrial-fibrillation-100575649","NCT06775028","Integrated Approach in Frail Older People with Atrial Fibrillation","AFFIRMO - Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People","AFFIRMO","Inclusion Criteria:\n\n* Outpatients of both sexes with age ≥65 years;\n* First diagnosed, paroxysmal, persistent, long-standing persistent or permanent AF, confirmed as per guideline-recommended diagnostic criteria for AF, e.g. with electrocardiogram (ECG) or Holter monitoring;\n* ≥1 additional long-term comorbidity, thus fulfilling the definition of multimorbidity: hypertension (treated with at least 2 antihypertensive drugs), coronary artery disease (CAD), peripheral artery disease, heart failure, stroke\u002FTIA, diabetes mellitus, COPD, CKD.\n\nExclusion Criteria:\n\n* Mechanical prosthetic heart valve or moderate\u002Fsevere mitral stenosis;\n* Patient unwilling to be enrolled and sign written informed consent;\n* Patient unable to understand the study and attend the follow-up;\n* Serious diseases with a life expectancy inferior to 12 months;\n* Patients included in other interventional studies.\n\nOnly for sites randomized to the iABC group:\n\n\\- Patient without a device suitable for iABC use.","65 Years",{"count":121,"type":21},1250,[92],"The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities.\n\nThe study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .",[125,126,127,128,129,130,131,132,133,134],"Atrial Fibrillation (AF)","Hypertension","Coronary Arterial Disease (CAD)","Heart Failure","COPD","Peripheral Arterial Disease","CKD","Diabetes Mellitus","Stroke","TIA (Transient Ischemic Attack)",[136,137,138],"iABC","Atrial Fibrillation","Cluster Trial","2025-01-09",{"date":141,"type":40},"2025-01-14",{"date":143,"type":40},"2024-04-11",{"date":145,"type":21},"2026-01-31",{"name":46,"class":47},50,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100537604","bring-up-3-heart-failure-100537604","NCT06279988","BRING-UP 3 Heart Failure","BRING-UP3HF","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Males and females at birth.\n3. Any ejection fraction level (level of ejection fraction measured in the 6 months preceding enrollment).\n4. Ambulatory chronic HF or Hospitalized de-novo or worsening HF.\n5. Signed informed consent\n\nDiagnosis will be made by the local attending physician following the ESC guidelines recommendations.\n\nExclusion Criteria:\n\n1. Active neoplasia or very severe disease compromising short-medium term life expectancy.\n2. Participation in interventional studies.\n3. Patients already enrolled into the study from another participating center or in the previous enrolling phase.",{"count":156,"type":21},10000,"The aim of this observational study is to assess the level of adherence to guideline recommendations regarding the management of patients with Heart Failure with Reduced Ejection Fraction (HFrEF); - the safety profile of the implementation of recommended treatments; - to monitor treatment patterns of patients with acute hert failure (HF); - to monitor treatment patterns of all patients with chronic HF irrespective of the level of ejection fraction (EF).",[128],"2024-02-27",{"date":161,"type":40},"2024-02-28",{"date":163,"type":40},"2023-09-15",{"date":165,"type":21},"2026-07-30",{"name":46,"class":47},187,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100537229","bring-up-prevention-100537229","NCT06275113","BRING-UP Prevention","Inclusion Criteria:\n\n* Both sexes at birth, age ≥18 years\n\nAt least one of the following clinical conditions:\n\n* Documented CAD defined as:\n\n  * Prior Acute Coronary Syndrom (ACS)\n  * Prior Coronary Artery Bypass Graft (CABG)\n  * Prior Percutaneous Coronary Intervention (PCI)\n* Documented PAD (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease, Ankle Brachial Index (ABI)\\\u003C90).\n* Documented CVD: Ischemic stroke, previous carotid vascular interventions.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Active neoplasia or very severe disease compromising short-medium term life expectancy.\n* Participation in interventional studies.\n* Patients already enrolled into the study from another participating center or in the previous enrolling phase.",{"count":175,"type":21},6000,"The aim of this observational study is to assess in patients with a documented athero-thrombotic event: coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral artery disease (PAD):\n\n* the level of adherence to guideline recommendations with the assumption to improve the rate of patients at goal for cholesterol levels.\n* the level of adherence to guideline recommendations and the rate of patients at goal for the other relevant and modifiable risk factors for cardiovascular event recurrence.",[178,179,130],"Ischemic Heart Disease","Cerebrovascular Disorders","2024-02-15",{"date":182,"type":40},"2024-02-23",{"date":163,"type":40},{"date":185,"type":21},"2026-06-30",{"name":46,"class":47},196,""]